European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III […]
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer / New approval based on data from the pivotal Phase III ARASENS […]
Quote Professor Funk Cancer immunotherapy with CAR-T cells is an important therapeutic strategy for lymphoma and leukaemia, but it can cause serious adverse reactions. Experts […]
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Phospho-Tau (181P) CSF (pTau181) assays have received […]
….to prioritize unhealthy cholesterol as a main public health issue The Global Heart Hub has today launched its Global Cholesterol Action Plan to reduce the […]
RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) (“Relief”), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected […]
• Responds to growing global demand for biosafety testing as essential requirement for drug development and commercialization • Expansion creates more than 500 new jobs […]
– Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients –– Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 […]
…First BTKi to Demonstrate Sustained Clinical Benefit for People with RMS through Three and a Half Years of Treatment This data suggests the long-term positive […]
Ad hoc announcement pursuant to Art. 53 LR Q3 sales grew +4% cc1 (-4% USD) Innovative Medicines (IM) sales grew +4% cc (-3% USD), driven […]
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLY-PNH trial met its two primary endpoints for superiority versus anti-C5 treatment in adult paroxysmal […]
Bulletin on Drug Safety – Current Issue 3/2022 Published The Bulletin on Drug Safety is a cooperation between the Federal Institute for Drugs and Medical […]
Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion’s Dispersome® technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer […]
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the submission of a New […]
Submission supported by comprehensive analytical and clinical data from new Phase I bridging pharmacokinetics study Adalimumab’s high-concentration 100 mg/mL formulation aims to provide an enhanced […]
Copyright © 2023 | WordPress Theme by MH Themes
